Mature results of MM-011: a phase I/II trial of liposomal doxorubicin, vincristine, dexamethasone, and lenalidomide combination therapy followed by lenalidomide maintenance for relapsed/refractory multiple myeloma.
about
Evolving paradigms in the treatment of relapsed/refractory multiple myeloma: increased options and increased complexityEvolving Paradigms in the Management of Multiple Myeloma: Novel Agents and Targeted Therapiesp38 MAPK differentially controls NK activating ligands at transcriptional and post-transcriptional level on multiple myeloma cells.Phase-I randomized trial of doxorubicin hydrochloride liposome injection versus Caelyx® in multiple myeloma.
P2860
Mature results of MM-011: a phase I/II trial of liposomal doxorubicin, vincristine, dexamethasone, and lenalidomide combination therapy followed by lenalidomide maintenance for relapsed/refractory multiple myeloma.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Mature results of MM-011: a ph ...... d/refractory multiple myeloma.
@en
Mature results of MM-011: a ph ...... d/refractory multiple myeloma.
@nl
type
label
Mature results of MM-011: a ph ...... d/refractory multiple myeloma.
@en
Mature results of MM-011: a ph ...... d/refractory multiple myeloma.
@nl
prefLabel
Mature results of MM-011: a ph ...... d/refractory multiple myeloma.
@en
Mature results of MM-011: a ph ...... d/refractory multiple myeloma.
@nl
P2093
P2860
P921
P356
P1476
Mature results of MM-011: a ph ...... d/refractory multiple myeloma.
@en
P2093
Aleksandr Lazaryan
Becky Habecker
Beth Faiman
Frederic J Reu
Gordan Srkalovic
Janice Reed
Jerome B Zeldis
Joel Waksman
John W Sweetenham
Kellie Bruening
P2860
P304
P356
10.1002/AJH.23639
P577
2014-02-24T00:00:00Z